Article Sidebar

PDF
Date Published: 12/06/2021
Abstract Views: 197
Views PDF: 178
DOI: https://doi.org/10.51298/vmj.v500i2.396
Issue
Vol. 500 No. 2 (2021)
Section
Các bài báo
How to Cite
Thị Huyền, P. . (2021). ASSESSMENT OF RESULTS AND SOME FACTORS AFFECTING IN FIRST LINEERLOTINIB TREATMENT OF NON SMALL CELL LUNG CANCER STAGE IV WITH EGFR MUTATION. Vietnam Medical Journal, 500(2). https://doi.org/10.51298/vmj.v500i2.396

ASSESSMENT OF RESULTS AND SOME FACTORS AFFECTING IN FIRST LINEERLOTINIB TREATMENT OF NON SMALL CELL LUNG CANCER STAGE IV WITH EGFR MUTATION

Phùng Thị Huyền

Main Article Content

Abstract

Objective: To evaluate the efficacy and some factors influencing on erlotinib treatment in the primary treatment of stage IV non-small cell lung cancer with EGFR gene mutation. Subjects and methods: A retrospective combined prospective study on 131 stage IV non-small cell lung cancer patients. Results: Complete response was 0,8%, partial response was 65,6%, disease control rate was 80,9%, no relationship was found between response rates and related factors. Conclusion: Erlotinib treatment in stage IV lung cancer with EGFR mutation is effective.

Article Details

Keywords

Non-small cell lung cancer, EGFR, tyrosin kinase inhibitor

References

1. GLOBOCAN. International agency for research on cancer. 2018.
2. Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. Mar 2012. 13(3):239-246. doi:10.1016/S1470-2045(11)70393-X.
3. Gao G, Ren S, Li A, et al. Epidermal growth factor receptor-tyrosine kinase inhibitor therapy is effective as first-line treatment of advanced non-small-cell lung cancer with mutated EGFR: A meta-analysis from six phase III randomized controlled trials. Int J Cancer. Sep 1 2012. 131(5):E822-829. doi:10.1002/ijc.27396.
4. Gridelli C, Rossi A. EURTAC first-line phase III randomized study in advanced non-small cell lung cancer: Erlotinib works also in European population. J Thorac Dis. Apr 1 2012. 4(2):219-220. doi:10.3978/j. issn.2072-1439.2012.03.03.
5. Zhou C, Wu YL, Chen G, et al. Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802). Ann Oncol. Sep 2015. 26(9):1877-1883. doi:10.1093/annonc/mdv276.
6. Nguyễn Minh Hà, Tạ Thành Văn và CS. Erlotinib bước một trên bệnh nhân ung thư phổi không tế bào nhỏ giai đoạn muộn có đột biến gen EGFR. Tạp chí nghiên cứu y học. 2014 2014.Phụ trương 91, 97-14.
7. Nguyễn Thanh Hoa, Lê Văn Quảng, Đỗ Hùng Kiên. Đánh giá kết quả điều trị bước một của thuốc erlotinib trên bệnh nhân ung thư phổi không tế bào nhỏ tại bệnh viện K. 2019 ed2019.